1834 Investment Advisors’s Aurinia Pharmaceuticals AUPH Stock Holding History

1834 Investment Advisors’s Portfolio AUPH Stock Details AUPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-3,000	Closed	-$30K	–	217
2022 Q2	$30K	Hold	3,000	–	–	﹤0.01%	308
2022 Q1	$37K	Sell	3,000 -250	-8%	-$3.86K	﹤0.01%	265
2021 Q4	$74K	Sell	3,250 -650	-17%	-$15.4K	0.01%	247
2021 Q3	$86K	Sell	3,900 -900	-19%	-$14.3K	0.01%	242
2021 Q2	$62K	Buy	4,800 +1,800	+60%	+$22.9K	0.01%	262
2021 Q1	$39K	Buy	+3,000	New	+$43.5K	0.01%	280

Other funds holding AUPH

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

1834 Investment Advisors's AUPH Position: Q3 2022 in Review

1834 Investment Advisors sold out of Aurinia Pharmaceuticals (AUPH) in Q3 2022, closing a stake of 3,000 shares — an estimated $30K sold.

1834 Investment Advisors first reported a position in AUPH in Q1 2021 and held it in 6 quarters. The position peaked at $86K in Q3 2021. 189 funds tracked by Wall St. Rank hold AUPH as of Q3 2022.

1834 Investment Advisors reported no remaining Aurinia Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
1834 Investment Advisors sold 3,000 Aurinia Pharmaceuticals shares in Q3 2022, an estimated $30K.
1834 Investment Advisors first reported a position in Aurinia Pharmaceuticals in Q1 2021 and held it in 6 quarters.
1834 Investment Advisors's Aurinia Pharmaceuticals position peaked at $86K in Q3 2021.
189 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q3 2022.

Based on 1834 Investment Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.